期刊
CURRENT GENE THERAPY
卷 15, 期 4, 页码 395-415出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1566523215666150710123830
关键词
Adeno-associated virus (AAV); Antisense oligonucleotides (AONs); Duchenne muscular dystrophy (DMD); Dystrophin; Exon skipping; In vivo
资金
- Higher Education Funding Council for England (HEFCE, UK) at the University of Wolverhampton
- Muscular Dystrophy UK (MDUK)
- Action Duchenne, UK (AD)
- French Muscular Dystrophy Association (AFM, France)
- Muscular Dystrophy UK [RA5/3068, RA3/3074, RA3/3002] Funding Source: researchfish
Duchenne muscular dystrophy (DMD), an X-linked inherited muscle-wasting disease primarily affecting young boys with prevalence of between1:3,5001: 5,000, is a rare genetic disease caused by defects in the gene for dystrophin. Dystrophin protein is critical to the stability of myofibers in skeletal and cardiac muscle. There is currently no cure available to ameliorate DMD and/or its patho-physiology. A number of therapeutic strategies including molecular-based therapeutics that replace or correct the missing or nonfunctional dystrophin protein have been devised to correct the patho-physiological consequences induced by dystrophin absence. We will review the current in vivo experimentation status (including preclinical models and clinical trials) for two of these approaches, namely: 1) Adeno-associated virus (AAV) mediated (micro) dystrophin gene augmentation/supplementation and 2) Antisense oligonucleotide (AON)-mediated exon skipping strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据